Science & Research

The late-stage biopharmaceutical asset targets bradykinin-mediated angioedema — a rare-disease space with limited oral …

As precision oncology expands BTK-inhibitor research, ingredient developers tracking immune-pathway mechanisms are watc…

A supplemental NDA has been filed with the FDA for the symptomatic dermographism subtype — a regulatory move that could…

Phase I data published in Clinical Cancer Research positions VCN-01 as a potential immuno-oncology primer — but the fin…

Sessions touch on AI-driven trial design and real-world evidence collection — tools with growing relevance for nutraceu…

Early interim data signal a potential breakthrough in locoregional tumor control, though the therapy sits outside conve…

PET-CT imaging outperformed CT alone in detecting therapeutic response, potentially reshaping monitoring protocols for …

Single-dose outpatient tolerability profile positions the therapy for community oncology center expansion as allogeneic…

Epigenetic enzyme inhibition enters a new data cycle as Oryzon's iadademstat shows continued signal in acute myeloid le…

Initial data presented at EHA 2026 suggest tolerability in relapsed/refractory AML and HR-MDS patients, including those…

The partnership signals growing biotech interest in modifier-gene pathways, with potential downstream implications for …

Four oral presentations and one poster will feature patient-reported outcomes and real-world utilization data for the b…

Stay ahead of the industry